Press releases
- Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
- Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
- Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
More ▼
Key statistics
As of last trade, Arrowhead Pharmaceuticals Inc (HDP1:FRA) traded at 24.01, 23.03% above the 52 week low of 19.52 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.01 |
---|---|
High | 24.01 |
Low | 24.01 |
Bid | 24.05 |
Offer | 24.41 |
Previous close | 23.85 |
Average volume | 2.41k |
---|---|
Shares outstanding | 124.20m |
Free float | 118.64m |
P/E (TTM) | -- |
Market cap | 3.23bn USD |
EPS (TTM) | -4.24 USD |
Data delayed at least 15 minutes, as of Jul 01 2024 07:20 BST.
More ▼